A Study to Evaluate Safety, Tolerability and Pharmacokinetics of ADC3680B in Subjects With Partly Controlled Atopic Asthma

A Randomised, Placebo-Controlled, Double-Blind, Parallel Group Phase II Study to Assess the Safety, Tolerability and Pharmacokinetics of ADC3680B in Subjects With Partly Controlled Atopic Asthma

This study is to examine the safety, tolerability, pharmacokinetics and functional activity of ADC3680B administered once daily for 28 days in subjects with partly controlled atopic asthma.

Inclusion Criteria:

• Partially controlled mild-moderate atopic asthma
• Receiving inhaled corticosteroids
• Non-smoker or former smoker
• Males and females aged 18 to 55 years inclusive
• If female, must be of non-childbearing potential

Exclusion Criteria:

• History of acute severe asthma attacks
• History of COPD
• Other serious respiratory or other medical condition which may interfere with the outcome of the study